Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim in Adult ITP
NCT01143038Phase 2Completed
- Sponsor
- Amgen
- Start
- Nov 2010
- Primary completion
- Sep 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of romiplostim in immune thrombocytopenia (ITP), sponsored by Amgen. Primary endpoint: Number of Months With Platelet Response During the 12-Month Treatment Period. Started Nov 2010; status: completed.
02
Drugs
romiplostim
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT01143038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01143038.